[en] Cervical cancer is a preventable disease, occurring in relatively young women. In the Netherlands, population-based cervical screening aims at women aged 30-60 years. We performed a population-based study of the incidence of invasive cervical cancer in the Netherlands to evaluate trends, with emphasis on age at time of diagnosis. Histologic diagnosis was retrieved from the Netherlands Cancer Registry for all women residing in the Netherlands with invasive cervical cancer between January 1, 1989, and December 31, 1998. In this 10-year period, the incidence rate of squamous cell carcinoma decreased significantly from 7.1/100,000 to 6.1/100,000 (p < 0.001), with the greatest decrease in women aged 60-74 (-5.5%). While the overall incidence rate of adenocarcinoma remained stable, it increased in women aged 15-29 (+15.8%) and in women aged 30-44 (+2.5%), though the number of cases was small. For squamous cell carcinoma, the incidence of stage II at diagnosis decreased most (-2.7%). There was no change in stage at diagnosis for adenocarcinoma. Most cases of cervical cancer, 60.5%, were detected between ages 30 and 60 years, i.e., the Dutch screening age interval. Cervical cancer in women below age 30 contributed 5.0% to the total incidence, with 3.0% occurring between ages 27 and 29. Thus, screening for cervical cancer in the Netherlands is associated with a decrease in the incidence of squamous cell carcinoma and adenocarcinoma incidence appears to be increasing in younger women.
Disciplines :
Genetics & genetic processes
Author, co-author :
BULK, Saskia ; Centre Hospitalier Universitaire de Liège - CHU > Génétique
Visser, Otto
Rozendaal, Lawrence
Verheijen, Rene H. M.
Meijer, Chris J. L. M.
Language :
English
Title :
Cervical cancer in the Netherlands 1989-1998: Decrease of squamous cell carcinoma in older women, increase of adenocarcinoma in younger women.
Publication date :
2005
Journal title :
International Journal of Cancer
ISSN :
0020-7136
eISSN :
1097-0215
Publisher :
John Wiley & Sons, Hoboken, United States - New York
Siesling S, van Dijck JA, Visser O, Coebergh JW. Trends in incidence of and mortality from cancer in the Netherlands in the period 1989-1998. Eur J Cancer 2003;39:2521-30.
van Ballegooijen M, Hermens R. Cervical cancer screening in the Netherlands. Eur J Cancer 2000;36:2244-6.
Hanselaar AG. Criteria for organized cervical screening programs. Special emphasis on the Netherlands program. Acta Cytol 2002;46: 619-29.
Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
Kaplan DW, Feinstein RA, Fisher MM, Klein JD, Olmedo LF, Rome ES, Yancy WS, Adams Hillard PJ, Sacks D, Pearson G, Frankowski BL, Piazza H.T. Condom use by adolescents. Pediatrics 2001;107: 1463-9.
Linos A, Riza E. Comparisons of cervical cancer screening programmes in the European Union. Eur J Cancer 2000;36:2260-5.
van der Sanden GA, Coebergh JW, Schouten LJ, Visser O, van Leeuwen FE. Cancer incidence in the Netherlands in 1989 and 1990: first results of the nationwide Netherlands Cancer Registry. Coordinating Committee for Regional Cancer Registries. Eur J Cancer 1995; 31A:1822-9.
Visser O, Coebergh JW, Otter R. Gynaecological tumours in the Netherlands 1989-1993. Utrecht: Netherlands Cancer Registry, 1997.
Bulk S, van Kemenade FJ, Rozendaal L, Meijer CJ. The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996. J Clin Pathol 2004;57: 388-93.
Visser O, Coebergh JW, van Dijck JAAM, Siesling S. Incidence of cancer in the Netherlands 1998. Utrecht: Vereniging van Integrale Kankercentra, 2002.
van den Akker-van Marie ME, van Ballegooijen M, Habbema JD. Low risk of cervical cancer during a long period after negative screening in the Netherlands. Br J Cancer 2003;88:1054-7.
Quinn M, Babb P, Jones J, Allen E. Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. BMJ 1999;318:904-8.
Bergstrom R, Sparen P, Adami HO. Trends in cancer of the cervix uteri in Sweden following cytological screening. Br J Cancer 1999; 81:159-66.
Anttila A, Pukkala E, Soderman B, Kallio M, Nieminen P, Hakama M. Effect of organised screening on cervical cancer incidence and mortality in Finland, 1963-1995: recent increase in cervical cancer incidence. Int J Cancer 1999;83:59-65.
Mitchell H, Medley G, Gordon I, Giles G. Cervical cytology reported as negative and risk of adenocarcinoma of the cervix: no strong evidence of benefit. Br J Cancer 1995;71:894-7.
Vizcaino AP, Moreno V, Bosch FX, Munoz N, Barros-Dios XM, Parkin DM. International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenosquamous cell carcinomas. Int J Cancer 1998;75:536-45.
Ponten J, Adami HO, Bergstrom R, Dillner J, Friberg LG, Gustafsson L, Miller AB, Parkin DM, Sparen P, Trichopoulos D. Strategies for global control of cervical cancer. Int J Cancer 1995;60:1-26.
Sparen P, Gustafsson L, Friberg LG, Ponten J, Bergstrom R, Adami HO. Improved control of invasive cervical cancer in Sweden over six decades by earlier clinical detection and better treatment. J Clin Oncol 1995;13:715-25.
Kjaer SK, Chackerian B, van den Brule AJ, Svare EI, Paull G, Walbomers JM, Schiller JT, Bock JE, Sherman ME, Lowy DR, Meijer CL. High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse). Cancer Epidemiol Biomarkers Prev 2001;10:101-6.
Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003;157: 218-26.
van den Akker-van Marle ME, van Ballegooijen M, van Oortmarssen GJ, Boer R, Habbema JD. Cost-effectiveness of cervical cancer screening: comparison of screening policies. J Natl Cancer Inst 2002; 94:193-204.
Zielinski GD, Snijders PJ, Rozendaal L, Daalmeijer NF, Risse EK, Voorhorst FJ, Jiwa NM, van der Linden HC, de Schipper FA, Runsink AP, Meijer CJ. The presence of high-risk HPV combined with specific p53 and pl6 INK4a expression patterns points to high-risk HPV as the main causative agent for adenocarcinoma in situ and adenocarcinoma of the cervix. J Pathol 2003;201:535-43.
Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-65.
van Duin M, Snijders PJ, Schrijnemakers HF, Voorhorst FJ, Rozendaal L, Nobbenhuis MA, van den Brule AJ, Verheijen RH, Heimerhorst TJ, Meijer CJ. Human papillomavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN II/III and viral clearance. Int J Cancer 2002;98:590-5.
Kraus I, Molden T, Erno LE, Skomedal H, Karlsen F, Hagmar B. Human papillomavirus oncogenic expression in the dysplastic portio; an investigation of biopsies from 190 cervical cones. Br J Cancer 2004;90:1407-13.
